Okay...so we have Donald sounding all super excited, and touting the results of all the secondary and tertiary endpoints, and to my scientific mind it seems there's a moutain of positive data there obviously, but the patient numbers are just too small....the only endpoint that had sufficient patient numbers to definitively prove anything was the primary.  

So we have the CEO of an obscure Canadian biotech pounding the bullish drum on the results from small patient subgroups, and Dr. Kausik Ray saying that Apabetalone should "probably" be subject to futher investigation...which is far from a ringing endorsement in my books. 

We need one of two things in my mind....first and foremost in a partner, the bigger the better.  And the second is like the first, a Key Opinion Leader to echo Don's bullish outlook.  We could get two in one if a Pfizer (or GSK, Merck, Sanofi...any BP) were to sign on in some fashion.